(Q43242171)

English

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation

scientific article published on 13 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Hideaki Miyake

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Toshifumi Kurahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Kazuki Yamanaka

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Yutaka Kondo

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Mototsugu Muramaki

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Atsushi Takenaka

6

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Taka-Aki Inoue

7

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Masato Fujisawa

8

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

13 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

515-519

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Targeted molecular therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

The future of tyrosine kinase inhibitors: single agent or combination?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.08.011

7 January 2021

Identifiers

10.1016/J.UROLONC.2009.08.011

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43242171&oldid=1984714505"